SCHEMBL22137693

SCHEMBL22137693

FC1(F)CCN(CCOc2ccc(Br)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.63
▸ PTGS2 P35354 1/20 0.63
▸ HRH3 Q9Y5N1 2/20 0.59
▸ ATM Q13315 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ KDM4E B2RXH2 3/20 0.51
▸ RECQL P46063 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ CHIT1 Q13231 1/20 0.49
▸ CHIA Q9BZP6 1/20 0.49
▸ PSMB1 P20618 3/20 0.49
▸ PSMB5 P28074 3/20 0.49
▸ PSMB2 P49721 2/20 0.49
▸ KCNA5 P22460 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ HTR1A P08908 1/20 0.46
▸ HTR7 P34969 1/20 0.46
▸ MCHR1 Q99705 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2018195 0.92 HRH3 (0.70) LTA4HPTGS2HRH3ATML3MBTL1
SCHEMBL82404 0.84 HRH3 (0.59) LTA4HHRH3KDM4EPSMB1PSMB5
SCHEMBL17198029 0.84 LTA4H (0.59) LTA4HHRH3KCNA5
SCHEMBL25305207 0.82 LTA4H (0.60) LTA4HPTGS2HRH3ATML3MBTL1
SCHEMBL229697 0.82 LTA4H (0.90) LTA4HPTGS2HRH3ATML3MBTL1
SCHEMBL14123709 0.80 HRH3 (0.54) LTA4HHRH3TSHRKDM4EPSMB1
SCHEMBL5116881 0.80 LTA4H (0.87) LTA4HPTGS2HRH3ATML3MBTL1
SCHEMBL227425 0.80 LTA4H (0.87) LTA4HPTGS2HRH3ATML3MBTL1
SCHEMBL227976 0.80 LTA4H (0.87) LTA4HPTGS2HRH3ATML3MBTL1
SCHEMBL23291256 0.80 HRH3 (0.57) LTA4HPTGS2HRH3PSMB1PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 — — US disclosed
US-20220079951-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD SAINT LOUIS UNIVERSITY (US) 2022-03-17 — — US disclosed
WO-2020132004-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD SAINT LOUIS UNIVERSITY (US) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220079951-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD BRDT, PHKB, BET1 LTA4H 4417/4885PTGS2 4415/4885HRH3 3672/4885
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD BRDT, BET1, PHKB LTA4H 3972/4885PTGS2 4614/4885HRH3 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback